meta|evidence oncology

Living systematic review and meta-analysis

metastatic, hormone-sensitive prostate cancer 11
renal cell cancer (RCC)

endocrine therapy
androgen deprivation therapy (ADT)
abiraterone plus ADT
abiraterone plus docetaxel plus ADT
apalutamide plus ADT
darolutamide plus doxetaxel plus ADT
docetaxel plus ADT
enzalutamide
enzalutamide plus ADT

versus all
vs endocrine therapy
vs androgen deprivation therapy (ADT)
vs docetaxel plus ADT

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -